Full-Time

QA Senior Manager

Posted on 4/15/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior, Expert

Hyderabad, Telangana, India

Category
QA & Testing
Quality Assurance
Required Skills
Risk Management
Requirements
  • Doctorate degree and 2 years of quality and/or design space experience
  • Master’s degree and 8 to 10 years of quality and/or design space experience
  • Bachelor’s degree and 10 to 14 years of quality and/or design space experience
  • Diploma and 14 to 18 years of quality and/or design space experience
Responsibilities
  • Responsible for providing Quality technical expertise, Quality oversight, and a single point of Quality contact for Combination Product Operations activities.
  • Provide guidance on documentation structures created during development activities.
  • Responsible for identifying proper GMP or Non-GMP phase-appropriate documentation strategies and repositories required for the design and development process to ensure compliance with applicable regulations and Amgen procedures.
  • Act as QA contact for change controls for projects, and review and approve relevant Design Control documentation.
  • Creation and Maintenance of Design History File Index, Device Design Traceability Matrix, Quality Combination Product Plan, and EDO Control Plan, and contribute to Design Control Phase Design Reviews.
  • Provide Quality oversight of Design Characterization, Verification, and Validation activities.
  • Ensure adherence to all relevant development final product regulations and standards.
  • Contribute to content and review of regulatory submissions and RTQs, and support audits and inspections for associated projects.
  • Responsible for ensuring program alignment and proper linkages within the Design and Development Plans, Risk Management Documentation, and EDO Control Plans.
  • Provide oversight and review of Human Factors Engineering (HFE) Protocols and Reports, as well as onboarding and auditing HFE suppliers.
  • Participate in deviation, CAPA, & Complaint investigations for commercial programs.
  • Collaborate to develop complete formal written responses.
  • Acts as independent reviewer for other combination product program design reviews.
  • Partner with CPO to contribute to management review, including topic selection.
  • Provides quality advice to teams on regulatory strategy.
Desired Qualifications
  • Quality and manufacturing experience in biotech or pharmaceutical industry
  • Experienced in NPI/NPD
  • Ability to convey and defend quality perspective to various levels of stakeholders
  • Participate in full audit cycle
  • Ability to interface with Regulators, and articulate knowledge of their process
  • Ability to respond to RTQs both verbally and in writing
  • Ability to interpret technical standards, internal requirements, and regulations
  • Bachelor’s Degree in a Science Field
  • Leadership skills and the ability to oversee multiple complex projects simultaneously
  • Working knowledge of quality engineering and/or mechanical engineering
  • Familiar with final products including applicable guidance, regulations and standards (e.g., MDR, ISO 14971, ICH Q9, ICH Q8, ICH Q10, ISO 13485, EU Annex 1, 21 CFR parts 4, 820, 210 and 211)
  • Prior experience leading and/or working as part of a combination product launch team
  • Able to successfully manage workload to timelines
  • Ability to effectively negotiate a position after taking feedback from multiple sources
  • Ability to operate in a matrixed or team environment with site, functional, and executive leadership
  • Experience driving decision making by using DAI principles
  • Understanding of industry requirements/expectations of a QMS
  • Understanding of the applicable manufacturing/testing processes (i.e. API, Drug Substance, Drug Product, Packaging, Device manufacturing processes)
  • Ability to travel +/- 20% of time to domestic and international Amgen sites

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are derived from living organisms, to address conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's products work by utilizing biological processes to create effective treatments for patients. Unlike many competitors, Amgen emphasizes a strong commitment to research and development, reinvesting a large portion of its earnings to discover new therapies. The goal of Amgen is to improve patient care by providing effective therapeutic solutions and expanding its pipeline of potential new treatments.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.